Results 51 to 60 of about 1,153,626 (336)

Approaches to overcome flow cytometry limitations in the analysis of cells from veterinary relevant species [PDF]

, 2020
BACKGROUND: Flow cytometry is a powerful tool for the multiparameter analysis of leukocyte subsets on the single cell level. Recent advances have greatly increased the number of fluorochrome-labeled antibodies in flow cytometry.
Debes, Gudrun F., Hunka, Julia, Riley, John T   +2 more
core   +1 more source

Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys [PDF]

, 2013
Human immunodeficiency virus type 1 (HIV-1)-specific monoclonal antibodies with extraordinary potency and breadth have recently been described. In humanized mice, combinations of monoclonal antibodies have been shown to suppress viraemia, but the ...
Barouch, Dan H., Beck, Matthew, Blackmore, Stephen, Borducchi, Erica N., Burton, Dennis R., Cabral, Crystal, Chakraborty, Arup K., Chang, Hui-Wen, Gupta, Sanjana, Klein, Florian, Lewis, Mark G., Liu, Jinyan, Moldt, Brian, Nkolola, Joseph P., Nussenzweig, Michel C., Oliveira, Thiago Y., Perry, James R., Poignard, Pascal, Rinaldi, William, Sanisetty, Srisowmya, Seaman, Michael S., Shekhar, Karthik, Smith, Jeffrey Y., Smith, Kaitlin M., Stephenson, Kathryn E., Whitney, James B.   +25 more
core   +3 more sources

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

High-concentration L-methionine as a potent antioxidant for oxidation resistance and stability enhancement in high-concentration antibody therapeutics

International Journal of Pharmaceutics: X
The development of high-concentration monoclonal antibody (mAb) formulations for subcutaneous administration is faces critical stability challenges, particularly oxidation and aggregation, which compromise efficacy and safety.
Xuekun Wang, Xinyu Zhang, Jin Xu, Shuhai Xu, Keyuan Huang, Qiaoling Ni, Xinyi Shen, Weitao Zhang, Tao Liu, Taimin Dong, Dan Mao, Chunguang Zheng, Wei Yu, Qingcheng Guo, Zhixin Li, Jiawei Cao, Fubo Han, Lusha Ji, Weizhu Qian, Sheng Hou, Jun Li, Ziqiao Sun, Jianxin Dai, Yajun Guo, Dapeng Zhang, Huaizu Guo   +25 more
doaj   +1 more source

Data on the characterization of follicle-stimulating hormone monoclonal antibodies and localization in Japanese eel pituitary

Data in Brief, 2016
Monoclonal antibodies were generated against recombinant follicle-stimulating hormone (rec-FSH) from Japanese eel Anguilla japonica; rec-FSH was produced in Escherichia coli and purified using Ni-NTA Sepharose column chromatography.In support of our ...
Dae-Jung Kim, Chae-Won Park, Munkhzaya Byambaragchaa, Shin-Kwon Kim, Bae-Ik Lee, Hyung-Kyu Hwang, Jeong-In Myeong, Sun-Mee Hong, Myung-Hwa Kang, Kwan-Sik Min   +9 more
doaj   +1 more source

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. [PDF]

, 2018
Our expanding knowledge of immunotherapy for solid tumors has led to an explosion of clinical trials aimed at urothelial carcinoma. The primary strategy is centered on unleashing the immune system by releasing the inhibitory signals propagated by ...
Chamie, Karim, Crosetti, Anna M, Cummings, Amy L, Drakaki, Alexandra, Faiena, Izak, Pantuck, Allan J   +5 more
core   +1 more source

Monoclonal antibodies against human astrocytomas and their reactivity pattern [PDF]

, 1987
The establishment of hybridomas after fusion of X63-Ag8.653 mouse myeloma cells and splenocytes from mice hyperimmunized against human astrocytomas is presented. The animals were primed with 5 × 106 chemically modified uncultured or cultured glioma cells.
B. Martin, Bourdon, Bullard, Bullard, Carrel, Coakham, Coakham, D. Stavrou, De Muralt, E. Keiditsch, Epenetos, F. Schmidberger, I. Funke, Jonak, K. Bise, Kearney, Kemshead, Krajewski, Köhler, Lanier, Posner, R. Kurrle, Roholl, Schnegg, Seeger, Sikora, Stavrou, Stavrou, Stavrou, Stavrou, Stavrou, Stavrou, Stavrou, Taub, U. Stocker, W. Eisenmenger, Wikstrand   +36 more
core   +1 more source

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

Integrated genomic and proteomic profiling reveals insights into chemoradiation resistance in cervical cancer

Molecular Oncology, EarlyView.
A comprehensive genomic and proteomic analysis of cervical cancer revealed STK11 and STX3 as a potential biomarkers of chemoradiation resistance. Our study demonstrated EGFR as a therapeutic target, paving the way for precision strategies to overcome treatment failure and the DNA repair pathway as a critical mechanism of resistance.
Janani Sambath, Irene A. George, Srikanth S. Manda, Prasanth Ariyannur, Ekta R. Dhawale, Raja Sekhar Kommu, Rajan Datar, Darshana Patil, Vinita Trivedi, Manisha Singh, Kumar Prabhash, Sewanti Limaye, Richa Chauhan, Prashant Kumar   +13 more
wiley   +1 more source

MONOCLONAL ANTIBODIES

Hematology, Transfusion and Cell Therapy
Obinutuzumab, an anti CD-20 monoclonal antibody, can be used in combination with venetoclax, ibrutinib or acalabrutinib in CLL patients with newly diagnosed or relaps patient's treatment indications. Another anti CD-20 monoclonal antibody, rituximab, has
Zekeriya Aksöz
doaj   +1 more source